We have some incredible news to share - an exciting breakthrough in the fight against histiocytic sarcoma, an aggressive and deadly cancer affecting our beloved canine companions. A newly funded study is underway, exploring the potential of a cancer drug to revolutionize the treatment landscape for dogs battling this devastating disease.

The multi-center clinical trial, supported by the Bernese Mountain Dog Club of America through Morris Animal Foundation's Donor-Inspired Study program, has assembled a team of researchers from Michigan State University, University of Florida, University of Wisconsin, and Virginia Tech to investigate a promising solution.

Background

Histiocytic sarcoma was first identified in Bernese mountain dogs in the late 1970s, but it has since been observed in several other breeds, making it a pressing concern for the entire dog community. Traditional chemotherapeutic drugs have shown limited success in improving treatment outcomes, especially with the disseminated form of the disease, leaving veterinarians and pet owners desperately searching for a more effective approach.

Enter Dr. Vilma Yuzbasiyan-Gurkan, the Principal Investigator of this groundbreaking study and a distinguished Professor of Microbiology, Molecular Genetics, and Small Animal Clinical Sciences at Michigan State University. Dr. Yuzbasiyan-Gurkan expressed her determination to find a solution: "Histiocytic sarcoma is a devastating disease, and we now have an opportunity to use a targeted approach in the treatment of this deadly cancer."

Enter trametinib

The drug at the center of this remarkable study is trametinib, known for its ability to target and inhibit the molecular pathway responsible for tumor growth. Extensive testing has shown promising results, demonstrating the drug's effectiveness against canine histiocytic sarcoma cell lines and even in mouse models replicating canine tumors. Furthermore, it has been found to be safe and tolerable for dogs.

"We are hopeful that the treatment will have a significant and positive impact on the affected dogs," said Dr. Yuzbasiyan-Gurkan. "We are always guided by data and look forward to seeing what the study will show."

This study may mark a turning point in veterinary oncology and the battle against histiocytic sarcoma, potentially leading to improved outcomes and longer, healthier lives for our canine companions.

Want to learn more about veterinary oncology? Check out our courses: myvetcandy.com